CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade is a research paper published in Cancer Discovery (2020). On theSindex it has a DataRank of 0. It has been cited 148 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH NCI NIDA
Grant: DP2CA238295
NIH NCI NIDA
Grant: 1R01CA231112
NIH NCI NIDA
Grant: U54CA209992-8697
NIH NCI NIDA
Grant: R33CA225498
NIH NCI NIDA
Grant: RF1DA048811
Damon Runyon Dale Frey Award
Grant: DFS-13-15
Melanoma Research Alliance
Grant: 412806
Melanoma Research Alliance
Grant: 16-003524
St-Baldrick's Foundation
Grant: 426685
Transformative Cancer Research
Grant: 17-20-01-CHEN
Mary Kay Foundation
Grant: 017-81
V Foundation
Grant: V2017-022
Ludwig Family Foundation, DoD
Grant: W81XWH-17-1-0235
Ludwig Family Foundation, DoD
Grant: W81XWH-20-1-0072
NIH NCI Memorial Sloan Kettering Cancer Center
Grant: T32GM007205
NIH NCI Memorial Sloan Kettering Cancer Center
Grant: F30CA250249
NIH
Grant: T32GM007499
National Institutes of Health
Grant: 5R33CA225498-03
Rapidly scalable platforms for direct in vivo screening of functional drivers in lethal cancers
National Institutes of Health
Grant: 1F30CA250249-01
Mechanosensation in tumorigenesis and metastasis
National Institutes of Health
Grant: 1RF1DA048811-01
New approaches for single cell tagging, editing and profiling of glial cells in vivo
National Institutes of Health
Grant: 5T32GM007499-33
Predoctoral Training Program in Genetics
National Institutes of Health
Grant: 1DP2CA238295-01
High-throughput in vivo genetics for immunotherapy target discovery
National Institutes of Health
Grant: 5T32GM007205-23
MEDICAL SCIENTIST TRAINING PROGRAM
National Institutes of Health
Grant: 1R01CA231112-01
(PQ4) Novel tools for in vivo study of genetic interactions in cancer progression
NCI NIH HHS
Grant: U54 CA209992
NCI NIH HHS
Grant: R01 CA231112
FWCI
5.71
Citation Percentile
1.0%
Influential Citations
4
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 2 of Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China
Additional file 2 of Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China
Additional file 3 of Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China
Additional file 3 of Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China
Additional file 2 of Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis
Additional file 2 of Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis
Additional file 1 of Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis
Additional file 1 of Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis
Additional file 1 of Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China
Additional file 1 of Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China